306 related articles for article (PubMed ID: 34312836)
1. Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia.
Hee Nam Y; Brensinger CM; Bilker WB; Flory JH; Leonard CE; Hennessy S
Clin Pharmacol Ther; 2022 Jan; 111(1):218-226. PubMed ID: 34312836
[TBL] [Abstract][Full Text] [Related]
2. Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues.
Han X; Chiang C; Leonard CE; Bilker WB; Brensinger CM; Li L; Hennessy S
Epidemiology; 2017 May; 28(3):459-468. PubMed ID: 28169935
[TBL] [Abstract][Full Text] [Related]
3. Serious Hypoglycemia and Use of Warfarin in Combination With Sulfonylureas or Metformin.
Nam YH; Brensinger CM; Bilker WB; Leonard CE; Han X; Hennessy S
Clin Pharmacol Ther; 2019 Jan; 105(1):210-218. PubMed ID: 29885251
[TBL] [Abstract][Full Text] [Related]
4. Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: A retrospective cohort study.
Leonard CE; Han X; Brensinger CM; Bilker WB; Cardillo S; Flory JH; Hennessy S
Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):9-18. PubMed ID: 29108130
[TBL] [Abstract][Full Text] [Related]
5. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
6. Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas.
Parekh TM; Raji M; Lin YL; Tan A; Kuo YF; Goodwin JS
JAMA Intern Med; 2014 Oct; 174(10):1605-12. PubMed ID: 25179404
[TBL] [Abstract][Full Text] [Related]
7. Sulfonylureas and Metformin Were Not Associated With an Increased Rate of Serious Bleeding in Warfarin Users: A Self-Controlled Case Series Study.
Nam YH; Han X; Brensinger CM; Bilker WB; Leonard CE; Hennessy S
Clin Pharmacol Ther; 2020 Nov; 108(5):1010-1017. PubMed ID: 32392373
[TBL] [Abstract][Full Text] [Related]
8. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
[TBL] [Abstract][Full Text] [Related]
9. Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis.
Romley JA; Gong C; Jena AB; Goldman DP; Williams B; Peters A
BMJ; 2015 Dec; 351():h6223. PubMed ID: 26643108
[TBL] [Abstract][Full Text] [Related]
10. Variations in tissue selectivity amongst insulin secretagogues: a systematic review.
Abdelmoneim AS; Hasenbank SE; Seubert JM; Brocks DR; Light PE; Simpson SH
Diabetes Obes Metab; 2012 Feb; 14(2):130-8. PubMed ID: 21923736
[TBL] [Abstract][Full Text] [Related]
11. Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis.
Huang HK; Yeh JI
Diabetes Res Clin Pract; 2019 Jun; 152():103-110. PubMed ID: 31108137
[TBL] [Abstract][Full Text] [Related]
12. Deintensification of Treatment With Sulfonylurea and Insulin After Severe Hypoglycemia Among Older Adults With Diabetes.
Alexopoulos AS; Kahkoska AR; Pate V; Bradley MC; Niznik J; Thorpe C; Stürmer T; Buse J
JAMA Netw Open; 2021 Nov; 4(11):e2132215. PubMed ID: 34726745
[TBL] [Abstract][Full Text] [Related]
13. Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins.
Schelleman H; Han X; Brensinger CM; Quinney SK; Bilker WB; Flockhart DA; Li L; Hennessy S
Br J Clin Pharmacol; 2014 Sep; 78(3):639-48. PubMed ID: 24548191
[TBL] [Abstract][Full Text] [Related]
14. Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
Diabetes Res Clin Pract; 2015 Jan; 107(1):104-12. PubMed ID: 25458330
[TBL] [Abstract][Full Text] [Related]
15. Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics.
Leonard CE; Bilker WB; Brensinger CM; Han X; Flory JH; Flockhart DA; Gagne JJ; Cardillo S; Hennessy S
Clin Pharmacol Ther; 2016 May; 99(5):538-47. PubMed ID: 26566262
[TBL] [Abstract][Full Text] [Related]
16. Coadministration of co-trimoxazole with sulfonylureas: hypoglycemia events and pattern of use.
Tan A; Holmes HM; Kuo YF; Raji MA; Goodwin JS
J Gerontol A Biol Sci Med Sci; 2015 Feb; 70(2):247-54. PubMed ID: 24858839
[TBL] [Abstract][Full Text] [Related]
17. Hypoglycemia in hospitalized patients treated with sulfonylureas.
Deusenberry CM; Coley KC; Korytkowski MT; Donihi AC
Pharmacotherapy; 2012 Jul; 32(7):613-7. PubMed ID: 22570146
[TBL] [Abstract][Full Text] [Related]
18. Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia.
Leonard CE; Brensinger CM; Aquilante CL; Bilker WB; Boudreau DM; Deo R; Flory JH; Gagne JJ; Mangaali MJ; Hennessy S
Diabetes Care; 2018 Apr; 41(4):713-722. PubMed ID: 29437823
[TBL] [Abstract][Full Text] [Related]
19. Individual sulfonylureas and serious hypoglycemia in older people.
Shorr RI; Ray WA; Daugherty JR; Griffin MR
J Am Geriatr Soc; 1996 Jul; 44(7):751-5. PubMed ID: 8675920
[TBL] [Abstract][Full Text] [Related]
20. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus.
Burge MR; Schmitz-Fiorentino K; Fischette C; Qualls CR; Schade DS
JAMA; 1998 Jan; 279(2):137-43. PubMed ID: 9440664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
